Brief: Aravive Reports Q4 2020 Financial Results

Aravive

16/03/2021 11:16

March 16 (Reuters) - Aravive Inc  ARAV.O :
    * Q4 LOSS PER SHARE $0.25
    * ARAVIVE - FIRST PATIENT DOSED IN PHASE 1B/2 TRIAL OF
AVB-500 IN
CLEAR CELL RENAL CELL CARCINOMA IN 1Q 2021; ON-TRACK TO REPORT
TOPLINE DATA IN 2H 2021
    * Q4 EARNINGS PER SHARE VIEW $-0.52 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX1wlYcC 
Further company coverage:  ARAV.O 

 ((Reuters.Briefs@thomsonreuters.com;))